Comparative Pharmacology
Head-to-head clinical analysis: AKNE MYCIN versus BENZAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKNE MYCIN versus BENZAMYCIN.
AKNE-MYCIN vs BENZAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis by blocking translocation of peptidyl-tRNA. Topically, it reduces Propionibacterium acnes colonization and exhibits anti-inflammatory properties.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Topical application of 2% solution twice daily to affected areas.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
None Documented
None Documented
2-3 hours (normal renal function); up to 24-36 hours in severe renal impairment
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Primarily renal (60-80% unchanged); minor biliary/fecal (15-30%)
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Category C
Category C
Topical Antibiotic
Topical Antibiotic